There are currently comprehensive clinical studies underway to determine drug interactions and other aspects of the Tabex application.
The manufacturer's warnings are as follows:
Drug interactions: No data is available on undesired interactions between Tabex and other pharmaceuticals.
There is not sufficient clinical experience with Tabex administration to patients with ischemic heart disease, cardiac impairment, cerebrovascular diseases, obliterating arterial diseases, hyperthyroidism, diabetes mellitus, renal and hepatic insufficiency. The use of the drug of these categories of patients should be performed only after the potential benefit has been weighed against the possible risks.
It would be advisable to consult a physicianon the subject.